MAPT and amyotrophic lateral sclerosis: However, tau reduction did not alter the age of disease onset or mortality in a mouse model of amyotrophic lateral sclerosis [33], providing further support for the conclusion that tau specifically contributes to functional and pathological abnormalities in experimental models of some neurodegenerative disorders but not of others.